Cencora reported its financial results for the first quarter (Q1) of fiscal year 2026. Revenue for the period was USD 85.93 billion, an increase of 5.5%. Gross profit rose 20.1% to USD 3.07 billion. Net income attributable to Cencora for the quarter was USD 560 million. Diluted earnings per share were USD 2.87, with diluted shares outstanding totaling 195.3 million. The company highlighted that revenue growth was primarily driven by a 5.0% increase in the U.S. Healthcare Solutions segment and a 9.6% increase in the International Healthcare Solutions segment. Cencora also completed the acquisition of OneOncology, strengthening its specialty MSO footprint and expanding its U.S. Healthcare Solutions business. The company raised its adjusted operating income growth guidance for fiscal year 2026 to a range of 11.5% to 13.5%, reflecting both the impact of the acquisition and strong segment performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cencora Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203562721) on February 04, 2026, and is solely responsible for the information contained therein.